A Phase 3 interventional study of NX-5948 and Pirtobrutinib in B-cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Nurix Therapeutics, Inc.. Recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by Nurix Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing pirtobrutinib in Lymphoma, B-Cell — 3 open to participants now, 8 under way, 6 of them phase 3. pirtobrutinib · Lymphoma, B-Cell.
Among the 10 studies testing pirtobrutinib in Lymphoma, B-Cell, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2026, is one of 6 in phase 3, and was the 9th registered.
885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.
Browse Lymphoma, B-Cell studies →3 of the 10 studies testing pirtobrutinib in Lymphoma, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
Loxo Oncology, Inc. · Sites in United States, Argentina, Australia and 20 more countries
Ages 18+
Sun Yat-sen University · Sites in China
Ages 18+
By country, each count listing its studies:
pirtobrutinib: first FDA approval 2023 (JAYPIRCA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 6
First in 2019; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 620 is above the median of 34 across 773 interventional studies indexed under Lymphoma, B-Cell.
Median enrollment 391 across the 10 interventional studies. Of the 2 that completed or were terminated, 1 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 4 most frequent:
Nurix Therapeutics, Inc. is the lead sponsor of 10 studies on the registry; 6 are open to participants now.
Nurix Therapeutics, Inc. has 2 studies filed under Lymphoma, B-Cell — fewer than ten, so there is no comparison to draw.
2 of the studies testing pirtobrutinib in Lymphoma, B-Cell that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05254743Phase 3Loxo Oncology, Inc.A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | 2027-10 |
| NCT04662255Phase 3Loxo Oncology, Inc.Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing pirtobrutinib in Lymphoma, B-Cell, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study will evaluate the efficacy and safety of NX-5948 (bexobrutideg) versus pirtobrutinib in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who are relapsed or refractory to prior covalent Bruton tyrosine kinase inhibitor (cBTKi) treatment.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other Inclusion/Exclusion criteria may apply as defined in the protocol.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: NX-5948
Drug: Pirtobrutinib
Administered orally once daily
Also known as: Bexobrutideg
Administered orally once daily per prescribing information
Also known as: JAYPIRCA
Progression-free survival (PFS) as assessed by Independent Review Committee (IRC)
Time from randomization to disease progression per 2018 International Workshop on CLL (iwCLL) or death due to any cause, whichever is earlier
Time frame: Up to approximately 3.5 years
Objective response rate (ORR) without partial response with lymphocytosis (PR-L) as assessed by IRC
Percentage of participants with best overall response of complete response (CR)/CR with incomplete marrow recovery (CRi), partial response (PR), or nodular PR, as assessed per 2018 iwCLL guidelines
Time frame: Up to approximately 2.5 years
Overall survival
Time from randomization to death from any cause
Time frame: Up to approximately 7 years
PFS as assessed by the investigator
Time from randomization to disease progression or death due to any cause, whichever is earlier
Time frame: Up to approximately 3.5 years
Objective response rate (ORR) with and without partial response with lymphocytosis (PR-L) as assessed by IRC and investigator
Percentage of participants with best overall response of complete response (CR)/CR with incomplete marrow recovery (CRi), partial response (PR) or nodular PR, or PR-L (for ORR with PR-L), as assessed per 2018 International Workshop on CLL (iwCLL) guidelines
Time frame: Up to approximately 3.5 years
Duration of response with and without PR-L as assessed by IRC and investigator
Time from the date of the first response to documented disease progression or death due to any cause, whichever is earlier
Time frame: Up to approximately 3.5 years
Time to next anti-CLL/SLL treatment as assessed by IRC and by investigator
Time from randomization to the date of next anti-CLL/SLL treatment
Time frame: Up to approximately 3.5 years
Change from baseline in global health status/quality of life on the European Organization for Research and Treatment of Cancer Quality of Life Cancer Questionnaire C30 with CLL module (EORTC QLQ-C30-CLL17)
Percentage of participants with a clinically meaningful change from baseline using the EORTC QLQ-C30-CLL17 questionnaire to assess global health and overall quality of life
Time frame: Baseline and up to approximately 3.5 years
Change from baseline in EuroQol-5 Dimensions, 5-level Questionnaire (EQ-5D-5L)
Percentage of participants with a clinically meaningful change from baseline using the EQ-5D-5L questionnaire to assess health outcomes
Time frame: Baseline and up to approximately 3.5 years
Number of participants with treatment-emergent adverse events
Time frame: Up to approximately 3.5 years
Pharmacokinetic profile of NX-5948
NX-5948 concentrations in blood samples
Time frame: Up to Cycle 13 Day 1 (each cycle is 28 days)
Number of participants with clinically significant changes from baseline in laboratory parameters
Laboratory parameters may include hematology, clinical chemistry, and urinalysis
Time frame: Up to approximately 3.5 years
Number of participants with clinically significant changes from baseline in vital signs
Vital signs include blood pressure, heart and respiratory rates, pulse oximetry, and temperature
Time frame: Up to approximately 3.5 years
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Oct 2029, 38 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: NX-5948 · Pirtobrutinib
Nurix Therapeutics, Inc.